{"id":"sancuso-patch","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Headache"},{"rate":"3-8%","effect":"Constipation"},{"rate":"5-15%","effect":"Application site reactions"},{"rate":"2-5%","effect":"Asthenia/fatigue"},{"rate":"2-4%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Granisetron is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced nausea and vomiting (CINV) by blocking serotonin signaling at peripheral and central sites. The transdermal patch formulation provides sustained drug delivery over several days, maintaining therapeutic levels without repeated dosing. This approach is particularly useful for patients undergoing highly emetogenic chemotherapy regimens.","oneSentence":"Sancuso is a granisetron transdermal patch that blocks serotonin 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:51.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of nausea and vomiting associated with emetogenic chemotherapy"},{"name":"Prevention of postoperative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT01596413","phase":"PHASE1","title":"Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years","status":"WITHDRAWN","sponsor":"Kyowa Kirin Pharmaceutical Development Ltd","startDate":"","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":""},{"nctId":"NCT01596426","phase":"PHASE1","title":"Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years","status":"WITHDRAWN","sponsor":"Kyowa Kirin Pharmaceutical Development Ltd","startDate":"","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":""},{"nctId":"NCT00868764","phase":"PHASE1","title":"An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-04","conditions":"Pharmacokinetics","enrollment":60},{"nctId":"NCT01073696","phase":"PHASE1","title":"Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-03","conditions":"Healthy","enrollment":16},{"nctId":"NCT00890565","phase":"PHASE1","title":"Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-05","conditions":"Healthy","enrollment":240},{"nctId":"NCT01596400","phase":"PHASE1","title":"Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years","status":"COMPLETED","sponsor":"Kyowa Kirin Pharmaceutical Development Ltd","startDate":"2012-05","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":19},{"nctId":"NCT00873197","phase":"PHASE1","title":"PK, Tolerability and Safety of the Co-administration of Sancuso® (Transdermal Granisetron) and IV Granisetron","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-04","conditions":"Healthy","enrollment":12},{"nctId":"NCT05027646","phase":"PHASE1","title":"Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2021-07-06","conditions":"Healthy Volunteers","enrollment":134},{"nctId":"NCT04472143","phase":"PHASE2","title":"Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-07-18","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":60},{"nctId":"NCT05325190","phase":"PHASE2","title":"Granisetron Transdermal Patch System for Prevention of CINV by CapeOX","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-10-10","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":57},{"nctId":"NCT04501211","phase":"PHASE2","title":"Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis","status":"WITHDRAWN","sponsor":"Indiana University","startDate":"2019-01-01","conditions":"Gastroparesis","enrollment":""},{"nctId":"NCT01536392","phase":"PHASE3","title":"Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-03","conditions":"Cancer of the Cervix","enrollment":76},{"nctId":"NCT04912271","phase":"PHASE3","title":"Granisetron Transdermal Patch for Prophylaxis of Delayed CINV","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-06-10","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":140},{"nctId":"NCT02457195","phase":"PHASE2","title":"Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2016-02","conditions":"Postoperative Nausea and Vomiting","enrollment":50},{"nctId":"NCT01275664","phase":"NA","title":"Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer","status":"TERMINATED","sponsor":"Gynecologic Oncology Group","startDate":"2011-06","conditions":"Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma","enrollment":4},{"nctId":"NCT01649258","phase":"PHASE1","title":"Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2012-09-04","conditions":"Breast Cancer, Nausea, Vomiting","enrollment":29},{"nctId":"NCT03017391","phase":"PHASE4","title":"Treatment Algorithm for Nausea and Vomiting in the Palliative Phase","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2017-01","conditions":"Nausea, Vomiting, Cancer","enrollment":20},{"nctId":"NCT01952886","phase":"PHASE2","title":"Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients","status":"WITHDRAWN","sponsor":"Duke University","startDate":"","conditions":"Malignant Glioma","enrollment":""},{"nctId":"NCT01659775","phase":"PHASE4","title":"Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2011-08","conditions":"Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)","enrollment":389},{"nctId":"NCT01662687","phase":"PHASE4","title":"Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2012-02","conditions":"Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)","enrollment":276}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"NAUSEA"},{"count":3,"reaction":"VOMITING"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"DISEASE PROGRESSION"},{"count":2,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":2,"reaction":"VERTIGO"},{"count":2,"reaction":"WEIGHT DECREASED"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"ATELECTASIS"}],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sancuso patch","genericName":"Sancuso patch","companyName":"LG Life Sciences","companyId":"lg-life-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sancuso is a granisetron transdermal patch that blocks serotonin 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Prevention of nausea and vomiting associated with emetogenic chemotherapy, Prevention of postoperative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}